Thiel Capital

Pioneering a biologically enhanced future for humanity.

Network Bio is a company that specializes in creating a clinical and molecular data library aimed at advancing precision medicine for common human diseases. Its platform serves as a centralized repository for clinical and molecular data, facilitating research by allowing scientists to identify patterns and correlations. This capability is essential for the development of new treatments and diagnostic tools, contributing to more personalized healthcare solutions. Through its innovative approach, Network Bio supports the research community in addressing significant health challenges.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, that specializes in developing device-based therapies for neurodegenerative diseases. The company focuses on the delivery and monitoring of cerebrospinal fluid (CSF) and employs a proprietary therapeutic platform designed to remove toxic proteins from the CSF. EnClear's initial products are aimed at enhancing the quality of life for patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, EnClear Therapies is dedicated to advancing treatments that can halt disease progression and extend patient lives.

Rollup is a software company that provides a collaborative platform aimed at enhancing the development and optimization of complex hardware and systems. Its primary offering leverages model-based systems engineering, which integrates engineering analysis, designs, and documentation into a cohesive framework. This approach allows teams to streamline their processes, reducing reliance on costly tools and specialized software licenses, while also minimizing the need for extensively trained engineers. By facilitating real-time communication and system modeling, Rollup enables teams to efficiently collaborate and innovate in the creation of advanced hardware solutions.

Neros Technologies specializes in autonomous drone services, focusing on enhancing defense capabilities through innovative technology solutions. The company develops a platform aimed at reducing vulnerabilities on the battlefield, specifically designed to support dismounted soldiers in combat situations. By leveraging advanced drone technology, Neros Technologies seeks to empower the defense sector, providing clients with tools that enhance operational effectiveness and safety.

Quantum system develops manufactures and sells unmanned aerial systems, which provide aerial intelligence to commercial and governmental clients around the world.

Heading Health is a technology-enabled mental health platform dedicated to enhancing access to affordable care. The company provides personalized treatment solutions that utilize evidence-based therapeutics and advanced technologies such as transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine. By leveraging these tools, Heading Health aims to deliver effective and convenient mental health services, helping patients achieve meaningful outcomes and improved well-being.

Generation Prime is a digital healthcare platform focused on providing women's healthcare services, particularly in the area of in-vitro fertilization (IVF) and related family planning and medical needs. The company aims to enhance accessibility and affordability of IVF treatments through a closed-loop system that integrates technology with healthcare delivery. By facilitating clinic roll-ups, Generation Prime enables healthcare professionals to offer services at reduced costs, thereby improving patient care and experience.

SPARK Neuro Inc. is a neuroscience company focused on quantifying brain data to enhance audience engagement in the advertising and entertainment sectors, as well as improving clinical care and therapeutic discovery in healthcare. Founded in 2013 and headquartered in New York, the company utilizes advanced neuroscience tools, including patented neural metrics and machine learning algorithms, to analyze brain activity. Its flagship product, SPARK Scan, is a 10-minute EEG-based evaluation that detects early signs of changes in brain function. By partnering with prestigious institutions, SPARK Neuro aims to deepen the understanding of neurological and psychiatric conditions while making brain health measurement and care more accessible for healthcare professionals.

Ready.net is a software development company that specializes in creating business and operational tools for internet service providers (ISPs). Founded in 2020 and headquartered in San Francisco, California, the company offers a product called Back Office Secret Sauce (BOSS). This innovative software enables ISP subscribers to manage their networks independently, facilitating tasks such as upgrading service plans, selecting additional services, paying bills online, and receiving assistance through a chatbot. Ready.net aims to enhance the operational efficiency of local ISPs while providing a user-friendly experience for their customers.

Alloy Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2017. The company focuses on democratizing access to essential drug discovery platforms and services, primarily through its Alloy-Gx platform. This innovative platform features a royalty-free suite of immunocompetent transgenic mice that facilitate in vivo human antibody discovery. Alloy Therapeutics has developed humanized transgenic antibody discovery technology, which offers broad, non-exclusive access to drug discovery tools, allowing scientists to engage in their antibody projects more efficiently and effectively. The company's mission is to enhance the drug discovery process by providing accessible and advanced resources for researchers in the field.

Vienna is a smart canvas for ideas. It is a place to collect thoughts and everything that comes with photos, videos, code, music, files, and, of course, text. They serve services for creators, students, and teams to build and discover ideas.

Inflection Points is a company that specializes in providing training and recruitment services within the bitcoin and cryptocurrency industry. It operates an employment and training platform designed to facilitate connections between employers and job seekers in this sector. The platform enables employers to search for and connect with candidates for various job vacancies, while also offering candidates opportunities to explore roles within the bitcoin and crypto world.

Regent is a maritime mobility company focused on transforming coastal transportation through the development of electric flying machines known as seagliders. These innovative vehicles operate just above the water's surface, effectively combining the high speed of an airplane with the cost efficiency of a boat. Designed to achieve speeds of up to 180 mph, seagliders offer a sustainable and efficient solution for regional travel, connecting coastal cities and islands. By replacing traditional ferries and short-haul aircraft, Regent aims to provide a safer and faster transportation option that enhances connectivity between coastal communities.

Mynaric AG, established in 2009 and headquartered in Gilching, Germany, specializes in laser communication solutions for high-speed, long-distance wireless data transmission between moving objects. The company offers a range of terminals including air-to-ground, air-to-air, space terminals, and optical ground stations, catering to applications in space, air, and ground sectors. Its products facilitate secure, high-data rate connectivity for satellite constellations, airborne networks, and other mobility-based applications.

Ex-Human is a company that specializes in creating customizable interactive artificial intelligence characters designed to enhance user engagement through hyper-realistic conversations. Their platform enables the development of digital humans that can communicate via text, audio, images, and video, making interactions engaging and entertaining. This technology is particularly beneficial for sectors such as gaming, dating, chatbots, and influencer marketing. By offering empathetic AI characters, Ex-Human aims to provide a unique user experience that captivates audiences for extended periods.

Bullish Global is a new blockchain-based cryptocurrency exchange designed to combine the performance, user privacy, and compliance offered by central order book technology with the vertically integrated user benefits of decentralized finance (DeFi) market architecture.

Angiex is a biotechnology company focused on developing vascular-targeted biotherapeutics aimed at treating cancer. Founded by leading scientists, the company specializes in antibody-drug conjugate therapies that address key aspects of endothelial biology, particularly angiogenesis. Angiex's lead product is designed to deliver conjugated payloads directly to the nucleus of tumor cells and to activated endothelium in various cancers and inflamed vessels. This innovative approach facilitates the targeted treatment of solid tumors, including pancreatic, lung, and liver cancers, as well as glioblastoma multiforme. The company operates from LabCentral in Cambridge and leverages intellectual property from Beth Israel Deaconess Medical Center to advance its therapeutic solutions.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

Voices is a live video streaming platform that allows creators to monetize their work through donations and subscriptions. Voices will assist content creators in making this a "stunning mass phenomenon," as well as "promote the growth of the creative economy's middle class."

Rational Vaccines is a preclinical stage company focused on developing innovative vaccines to address herpes simplex virus-related diseases. The company is dedicated to creating live-attenuated viral immunotherapeutics and prophylactic vaccine candidates aimed at reducing the spread of the virus and improving the management of symptoms associated with herpes infections. Through its research, Rational Vaccines aspires to revolutionize the treatment, prevention, and diagnosis of herpes and related conditions, ultimately enhancing the quality of life for individuals affected by these diseases.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

Ready.net is a software development company that specializes in creating business and operational tools for internet service providers (ISPs). Founded in 2020 and headquartered in San Francisco, California, the company offers a product called Back Office Secret Sauce (BOSS). This innovative software enables ISP subscribers to manage their networks independently, facilitating tasks such as upgrading service plans, selecting additional services, paying bills online, and receiving assistance through a chatbot. Ready.net aims to enhance the operational efficiency of local ISPs while providing a user-friendly experience for their customers.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, that specializes in developing device-based therapies for neurodegenerative diseases. The company focuses on the delivery and monitoring of cerebrospinal fluid (CSF) and employs a proprietary therapeutic platform designed to remove toxic proteins from the CSF. EnClear's initial products are aimed at enhancing the quality of life for patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, EnClear Therapies is dedicated to advancing treatments that can halt disease progression and extend patient lives.

Advano, also known as NanoStar, Inc., is a New Orleans-based company that specializes in silicon nanotechnology, focusing on the development of advanced silicon anode materials for lithium-ion batteries. Founded in 2014 and a graduate of Y Combinator in 2017, Advano offers scalable solutions that enhance the energy density and longevity of lithium-ion batteries by integrating or replacing traditional graphite components. Its innovative products cater to various industries, including electric vehicles and consumer electronics, and are designed to improve energy storage and charging capabilities. By providing low-cost, high-performance materials, Advano aims to support the domestic battery supply chain and facilitate the transition to sustainable energy solutions.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, that specializes in developing device-based therapies for neurodegenerative diseases. The company focuses on the delivery and monitoring of cerebrospinal fluid (CSF) and employs a proprietary therapeutic platform designed to remove toxic proteins from the CSF. EnClear's initial products are aimed at enhancing the quality of life for patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, EnClear Therapies is dedicated to advancing treatments that can halt disease progression and extend patient lives.

SPARK Neuro Inc. is a neuroscience company focused on quantifying brain data to enhance audience engagement in the advertising and entertainment sectors, as well as improving clinical care and therapeutic discovery in healthcare. Founded in 2013 and headquartered in New York, the company utilizes advanced neuroscience tools, including patented neural metrics and machine learning algorithms, to analyze brain activity. Its flagship product, SPARK Scan, is a 10-minute EEG-based evaluation that detects early signs of changes in brain function. By partnering with prestigious institutions, SPARK Neuro aims to deepen the understanding of neurological and psychiatric conditions while making brain health measurement and care more accessible for healthcare professionals.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Terminal Inc., established in 2017 with headquarters in San Francisco and offices across North America and Mexico, specializes in talent solutions for technology companies. The company facilitates the recruitment, onboarding, and management of remote global engineering teams, enabling businesses to scale efficiently. Terminal offers global talent acquisition services, market insights, operational support including HR, benefits, payroll, and stock option administration, along with access to a connected tech community.

Invicta Medical, Inc. is a medical technology company that specializes in developing innovative therapies for sleep apnea and snoring. Founded in 2013 and headquartered in Portola Valley, California, the company has created a wearable device that utilizes neurostimulation to detect and treat disturbed breathing. This device aims to overcome the limitations of traditional therapies, which are often costly, invasive, and have low compliance rates among patients. By offering a smart, comfortable, and cost-effective solution, Invicta Medical seeks to provide effective treatment options for individuals suffering from sleep disorders.

ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services.

3T Biosciences, Inc. is an immunotherapy company founded in 2017 and headquartered in Menlo Park, California. The company focuses on developing innovative drugs and medical research facilities aimed at offering cures for cancer-related diseases. By leveraging synthetic biology and machine learning, 3T Biosciences seeks to discover novel targets for treating cancer and other T-cell-mediated diseases, thereby enhancing treatment options available to healthcare providers and improving patient outcomes.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Angiex is a biotechnology company focused on developing vascular-targeted biotherapeutics aimed at treating cancer. Founded by leading scientists, the company specializes in antibody-drug conjugate therapies that address key aspects of endothelial biology, particularly angiogenesis. Angiex's lead product is designed to deliver conjugated payloads directly to the nucleus of tumor cells and to activated endothelium in various cancers and inflamed vessels. This innovative approach facilitates the targeted treatment of solid tumors, including pancreatic, lung, and liver cancers, as well as glioblastoma multiforme. The company operates from LabCentral in Cambridge and leverages intellectual property from Beth Israel Deaconess Medical Center to advance its therapeutic solutions.

Invicta Medical, Inc. is a medical technology company that specializes in developing innovative therapies for sleep apnea and snoring. Founded in 2013 and headquartered in Portola Valley, California, the company has created a wearable device that utilizes neurostimulation to detect and treat disturbed breathing. This device aims to overcome the limitations of traditional therapies, which are often costly, invasive, and have low compliance rates among patients. By offering a smart, comfortable, and cost-effective solution, Invicta Medical seeks to provide effective treatment options for individuals suffering from sleep disorders.

Legendary Entertainment is a media company that specializes in creating and distributing content for television and digital platforms globally. The company engages in the development, co-production, co-financing, and distribution of motion pictures, collaborating with other production studios to enhance its offerings. Legendary Entertainment is dedicated to producing content that appeals to mainstream audiences, with a particular emphasis on the influential fandom demographic. Its portfolio includes box-office films, television shows, and comic storylines, reflecting a commitment to delivering engaging entertainment across various media formats.